Eli Lilly and Company
Revenue Breakdown
| Fiscal Year | Zyprexa | Cialis | Alimta | Humalog | Humulin | Gemzar | Evista | Forteo | Strattera | Symbyax | Erbitux | Byetta | Trad jenta | Effient | Jardiance | Trulicity | Taltz | Olumiant | Verzenio | Emgality | Tyvyt | Cyramza | Baqsimi | Retevmo | Bebtelovimab | Mounjaro | Jaypirca | Zepbound | Omvoh | Ebglyss | Kisunla | Animal Health | Collaboration and Other Revenue | Other Pharmaceutical Products |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2015 | $1.04B | $2.31B | $2.47B | $2.84B | $1.31B | $0 | $0 | $1.35B | $784.0M | $0 | $683.3M | $0 | $429.6M | $518.5M | $85.6M | $248.3M | $0 | $0 | $0 | $0 | $0 | $384.3M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $3.18B | $0 | $2.32B |
| FY2016 | $816.3M | $2.47B | $2.16B | $2.84B | $1.28B | $0 | $0 | $1.50B | $752.4M | $0 | $687.2M | $0 | $457.6M | $509.3M | $285.9M | $925.7M | $113.1M | $0 | $0 | $0 | $0 | $614.1M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $3.16B | $0 | $2.62B |
| FY2018 | $485.4M | $2.16B | $2.12B | $3.00B | $1.34B | $0 | $0 | $1.58B | $623.1M | $0 | $637.3M | $0 | $529.6M | $470.1M | $658.3M | $3.20B | $937.5M | $13.6M | $129.4M | $162.5M | $0 | $821.4M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $3.20B |
| FY2019 | $343.3M | $890.6M | $1.69B | $2.82B | $1.29B | $0 | $0 | $1.41B | $698.8M | $0 | $0 | $0 | $503.7M | $0 | $944.8M | $4.13B | $1.37B | $42.4M | $580.4M | $162.5M | $0 | $925.2M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $248.5M | $4.48B |
| FY2020 | $0 | $622.1M | $1.25B | $2.63B | $1.23B | $0 | $0 | $1.05B | $816.0M | $0 | $0 | $0 | $478.2M | $0 | $1.24B | $5.05B | $1.79B | $88.4M | $912.7M | $383.9M | $0 | $883.3M | $0 | $0 | $810.2M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $309.8M | $5.13B |
| FY2021 | $0 | $810.0M | $1.23B | $2.45B | $1.22B | $0 | $0 | $802.2M | $790.0M | $0 | $0 | $0 | $0 | $0 | $1.49B | $6.47B | $2.21B | $111.4M | $1.35B | $550.8M | $0 | $1.03B | $0 | $0 | $2.24B | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $378.1M | $4.97B |
| FY2022 | $0 | $0 | $927.8M | $2.06B | $1.02B | $0 | $0 | $612.9M | $0 | $0 | $0 | $0 | $0 | $0 | $2.06B | $7.44B | $2.48B | $179.2M | $2.01B | $650.9M | $0 | $971.0M | $0 | $0 | $1.20B | $482.5M | $0 | $0 | $0 | $0 | $0 | $0 | $511.2M | $5.04B |
| FY2023 | $0 | $0 | $226.7M | $1.63B | $796.8M | $0 | $0 | $580.4M | $0 | $0 | $0 | $0 | $0 | $0 | $2.57B | $7.13B | $2.76B | $168.5M | $3.86B | $678.4M | $0 | $1.01B | $0 | $0 | $0 | $5.16B | $128.0M | $175.8M | $0 | $0 | $0 | $0 | $1.09B | $6.15B |
| FY2024 | $0 | $0 | $0 | $1.28B | $627.5M | $0 | $0 | $466.8M | $0 | $0 | $0 | $0 | $0 | $0 | $3.23B | $6.23B | $3.10B | $154.2M | $5.08B | $746.5M | $0 | $1.08B | $0 | $0 | $0 | $11.54B | $320.0M | $3.03B | $0 | $0 | $0 | $0 | $1.30B | $6.85B |